MedTrace Logo

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

NCT05663710 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-05

No results posted yet for this study

Summary

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

Conditions

Interventions

DRUG

177Lu girentuximab

Given by IV (vein)

DRUG

Nivolumab

Given by IV (vein)

DRUG

Cabozantinib

Given by PO

DRUG

ArabinoFuranosylGuanine [18F]F-AraG

Given by IV (vein)

Sponsors & Collaborators

  • Telix Pharmaceuticals (Innovations) Pty Limited

    collaborator INDUSTRY

  • United States Department of Defense

    collaborator FED

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Eric Jonasch, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2027-10-30
Completion
2027-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05663710 on ClinicalTrials.gov